When should intravenous iron be given and what dosing regimen is recommended for an adult weighing at least 50 kg with hemoglobin less than 10 g/dL?

Intravenous Iron Administration for Adults ≥50 kg with Hemoglobin <10 g/dL

For adults weighing at least 50 kg with hemoglobin less than 10 g/dL, administer ferric derisomaltose (FDI) 1000 mg as a single total dose infusion diluted in 100 mL normal saline over 20-30 minutes, or ferric carboxymaltose (FCM) 750 mg twice, one week apart. 1

When to Give IV Iron

Intravenous iron should be used when:

• The patient does not tolerate oral iron
• Ferritin levels fail to improve despite a trial of oral iron
• The patient has a condition where oral iron absorption is impaired 2

Specific conditions requiring IV iron include:

• Active inflammatory bowel disease with compromised absorption 2
• Post-bariatric surgery (particularly procedures disrupting duodenal absorption) 2
• Chronic kidney disease
• Congestive heart failure with iron deficiency
• Ongoing blood loss (heavy menstrual bleeding, angiodysplasia, hereditary hemorrhagic telangiectasia) 1

Recommended Dosing Regimens

First-Line Formulation: Ferric Derisomaltose (FDI)

FDI is the preferred formulation because it is the only FDA-labeled total dose infusion and the first IV iron to demonstrate statistically significant reduction in cardiovascular death in heart failure patients 1.

Dosing:

• 1000 mg as a single infusion for patients ≥50 kg
• Alternative: Up to 20 mg/kg, not exceeding 1500 mg
• Dilute in 100 mL normal saline
• Infuse over 20-30 minutes
• No test dose required 1

Alternative: Ferric Carboxymaltose (FCM)

Dosing:

• 750 mg twice, administered one week apart (total 1500 mg)
• Dilute in 100 mL normal saline
• Infuse over 20-30 minutes 1

Critical caveat: FCM causes treatment-emergent hypophosphatemia in 50-74% of patients, potentially leading to the "6H syndrome" (hyperphosphaturic hypophosphatemia with high FGF23, hypovitaminosis D, hypocalcemia, secondary hyperparathyroidism) which can cause bone pain, osteomalacia, and fractures. Avoid FCM in patients requiring repeat infusions 1, 3.

Monitoring and Expected Response

Laboratory evaluation timing:

• Check CBC and iron parameters (ferritin, TSAT) 4-8 weeks after the last infusion
• Do not check iron parameters within 4 weeks of total dose infusion—circulating iron interferes with assays 1

Expected hemoglobin response:

• Increase within 1-2 weeks of treatment
• Should increase by 1-2 g/dL within 4-8 weeks 1
• Mean increase of approximately 26.7 g/L at 5-7 weeks 4

Target iron parameters (without inflammation):

• Ferritin: ≥50 ng/mL (regardless of sex)
• TSAT: ≥20% 1

Diagnostic Considerations for Iron Deficiency

In the absence of inflammation:

• Ferritin <50 ng/mL confirms iron deficiency
• TSAT <20% has high sensitivity for absolute or functional iron deficiency 1

With inflammation present:

• Ferritin may be falsely elevated as an acute phase reactant
• TSAT <20% remains reliable for diagnosing iron deficiency
• Ferritin <100 ng/mL has low sensitivity (35-48%) in inflammatory states
• Consider soluble transferrin receptor (sTfR) if available—elevated in iron deficiency and unaffected by inflammation 1

Safety Profile

All modern IV iron formulations have similar safety profiles:

• True anaphylaxis is very rare (<1% moderate to severe reactions) 2, 3
• Most reactions are complement activation-related pseudo-allergy (infusion reactions), not true allergic reactions
• Treat infusion reactions accordingly, not as anaphylaxis 2

Frequency of Repeat Administration

Single infusion suffices if:

• The underlying cause of iron deficiency has been eliminated 1

Multiple administrations necessary for:

• Ongoing blood loss (menorrhagia, GI bleeding)
• Malabsorption conditions (celiac disease, autoimmune gastritis, post-bariatric surgery)
• Active inflammatory bowel disease 1

Frequency depends on:

• Degree of ongoing blood loss
• Severity of malabsorption
• Monitor ferritin and TSAT every 4-8 weeks to guide repeat dosing 1

Key Clinical Pitfalls

• Avoid checking iron studies too early—wait 4-8 weeks post-infusion
• Avoid FCM for repeat dosing—risk of severe hypophosphatemia
• Don't rely solely on ferritin in inflammatory conditions—use TSAT
• Formulations requiring >2 infusions are not preferred—increases clinic visits and costs 2
• 1000 mg total dose is sufficient for most patients with hemoglobin <10 g/dL 4